Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 14(1): 19273, 2024 08 20.
Artigo em Inglês | MEDLINE | ID: mdl-39164295

RESUMO

Extracellular vesicles (EVs) from mesenchymal stem cells (MSCs), specifically those preconditioned with deferoxamine (DFO) in canine adipose tissue-derived MSCs (cAT-MSCs), were explored for treating autoimmune diseases. This study assessed the effects of DFO-preconditioned EVs (EVDFO) in an experimental autoimmune encephalomyelitis (EAE) mouse model. cAT-MSCs were treated with DFO for 48 h, after which EVs were isolated. EAE mice received intranasal EV or EVDFO treatments and were euthanized following histopathologic analysis; RNA and protein expression levels were measured. Histologically, EV and EVDFO groups showed a significant reduction in inflammatory cell infiltration and demyelination. Immunofluorescence revealed increased CD206 and Foxp3 expression, indicating elevated M2 macrophages and regulatory T (Treg) cells, particularly in the EVDFO group. Treg cells also notably increased in the spleen of EVDFO -treated mice. STAT3 and pSTAT3 proteins were upregulated in the EAE groups compared to the naïve group. However, following EV treatment, STAT3 expression decreased compared to the EAE group, whereas pSTAT3 expression was similar in both the EV and EAE groups. In conclusion, EVDFO treatment resulted in reduced STAT3 expression, suggesting its role in T cell regulation and the potential of EVDFO in modulating the STAT3 pathway for reducing inflammation more effectively than non-preconditioned EVs.


Assuntos
Desferroxamina , Encefalomielite Autoimune Experimental , Vesículas Extracelulares , Inflamação , Células-Tronco Mesenquimais , Fator de Transcrição STAT3 , Linfócitos T Reguladores , Animais , Encefalomielite Autoimune Experimental/patologia , Encefalomielite Autoimune Experimental/tratamento farmacológico , Encefalomielite Autoimune Experimental/metabolismo , Vesículas Extracelulares/metabolismo , Vesículas Extracelulares/transplante , Fator de Transcrição STAT3/metabolismo , Camundongos , Cães , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/metabolismo , Desferroxamina/farmacologia , Desferroxamina/uso terapêutico , Células-Tronco Mesenquimais/metabolismo , Inflamação/patologia , Feminino , Modelos Animais de Doenças
2.
PLoS One ; 19(5): e0303136, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38743689

RESUMO

Superoxide dismutase (SOD) is an antioxidant enzyme that protects the body from free radicals. It has both antioxidant and immunomodulatory properties, inducing macrophage polarization from M1 to M2. Macrophages, key mediators of the innate immune response, are divided into the M1 (pro-inflammatory) and M2 (anti-inflammatory) subtypes. In this study, we aimed to assess the antioxidant and neuroprotective effects of SOD on nerve cells and its immunomodulatory effects on macrophages. We observed that SOD inhibited the accumulation of reactive oxygen species and enhanced the viability of H2O2-treated nerve cells. Furthermore, SOD reduced the degree of necrosis in nerve cells treated with the conditioned medium from macrophages, which induced inflammation. In addition, SOD promoted the M1 to M2 transition of macrophages. Our findings suggest that SOD protects nerve cells and regulates immune responses.


Assuntos
Macrófagos , Fármacos Neuroprotetores , Espécies Reativas de Oxigênio , Superóxido Dismutase , Animais , Superóxido Dismutase/metabolismo , Camundongos , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Macrófagos/metabolismo , Humanos , Fármacos Neuroprotetores/farmacologia , Células RAW 264.7 , Espécies Reativas de Oxigênio/metabolismo , Neuroblastoma/imunologia , Neuroblastoma/patologia , Linhagem Celular Tumoral , Peróxido de Hidrogênio/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Antioxidantes/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA